TNF-α promotes c-REL/ΔNp63α interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer

Cancer Research

Volumn 71, Issue 21, 2011, Pages 6867-6877

  Lu, Hai ^a   Yang, Xinping ^a   Duggal, Praveen ^a   Allen, Clint T ^a   Yan, Bin ^a   Cohen, Jonah ^a   Nottingham, Liesl ^a   Romano, Rose Anne ^c   Sinha, Satrajit ^c   King, Kathryn E ^b   Weinberg, Wendy C ^b   Chen, Zhong ^a   Van Waes, Carter ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA NP63ALPHA PROTEIN; PROTEIN TAP73; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR REL; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER INHIBITION; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DNA BINDING MOTIF; GENE OVEREXPRESSION; GENE REPRESSION; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; NOXA GENE; P21WAF1 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; PUMA GENE; REGULATORY MECHANISM; TUMOR SUPPRESSOR GENE;

ACTIVE TRANSPORT, CELL NUCLEUS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BINDING SITES; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE, TUMOR; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA, NEOPLASM; DNA-BINDING PROTEINS; DRUG RESISTANCE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, REL; HEAD AND NECK NEOPLASMS; HUMANS; MULTIPROTEIN COMPLEXES; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEINS;

EID: 80155126633     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2460     Document Type: Article

References (38)

1. Robles AI, Harris CC. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol 2010;2:a001016.
2. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007;357:2552-61. (Pubitemid 350294222)
3. King KE, Weinberg WC. P63: Defining roles in the morphogenesis, homeostasis and neoplasia of the epidermis. Cancer Res 2008;68: 5122-31.
4. Rosenbluth JM, Pietenpol JA. The jury is in: p73 is a tumor suppressor afterall. Genes Dev 2008;22:2591-5.
5. De Young, Ellisen LW. P63 and p73 in human cancer: defining the network. Oncogene 2007;26:5169-83.
6. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361-71.
7. Younes F, Quartey EL, Kiguwa S, Partridge M. Expression of TNF and the 55-kDa TNF receptor in epidermis, oral mucosa, lichen planus and squamous cell carcinoma. Oral Dis 1996;2:25-31. (Pubitemid 126602146)
8. Duffey DC, Crowl-Bancroft CV, Chen Z, Ondrey FG, Nejad-Sattari M, Dong G, et al. Inhibition of transcription factor nuclear factor-kappaB by a mutant inhibitor-kappaBalpha attenuates resistance of human head and neck squamous cell carcinoma to TNF-alpha caspase-mediated cell death. Br J Cancer 2000;83:1367-74.
9. Beg AA, Baldwin AS Jr. Activation of multiple NF-kappaB/Rel DNA binding complexes by tumor necrosis factor. Oncogene 1994;9: 1487-92.
10. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996;274:784-7. (Pubitemid 26398259)
11. Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2007;6: 37-50. (Pubitemid 46206667)
12. Lee TL, Yeh J, Friedman J, Yan B, Yang X, Yeh NT, et al. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer 2008; 122:1987-98. (Pubitemid 351441187)
13. Allen C, Saigal K, Nottingham L, Arun P, Chen Z, Van Waes C. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer. Clin Cancer Res 2008;14:4175-85.
14. Liu CJ, Lin SC, Chen YJ, Chang KM, Chang KW. Array-comparative genomic hybridization to detect genomewide changes in microdissected primary and metastatic oral squamous cell carcinomas. Mol Carcinog 2006;45:721-31.
15. King KE, Ponnamperuma RM, Allen C, Lu H, Duggal P, Chen Z, et al. The p53 homologue DeltaNp63alpha interacts with the nuclear factor- kappaB pathway to modulate epithelial cell growth. Cancer Res 2008;68:5122-31.
16. Yan B, Yang X, Lee TL, Friedman J, Tang J, Van Waes C, et al. Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs for p53, nuclear factor-kappaB and other signal transcription factors in head and neck squamous cell carcinoma. Genome Biol 2007;8:R78.
17. Friedman J, NottinghamL, Duggal P, Pernas FG, Yan B, Yang XP, et al. Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer. Clin Cancer Res 2007;13:6568-78. (Pubitemid 350206790)
18. Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, et al. Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck 2010;32:417-26.
19. Lee TL, Yang XP, Yan B, Friedman J, Duggal P, Bagain L, et al. A novel nuclear factor-{kappa}B gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res 2007;13:5680-91. (Pubitemid 47591640)
20. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000;157:1769-75.
21. Thurfjell N, Coates PJ, Vojtesek B, Benham-Motlagh P, Eisold M, Nylander K. Endogenous p63 acts as a survival factor for tumour cells of SCCHN origin. Int J Mol Med 2005;16:1065-70.
22. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25. (Pubitemid 23346378)
23. Westfall MD, Mays DJ, Sniezek JC, Pietenpol JA. The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol 2003;23:2264-76. (Pubitemid 36351010)
24. Cheung N, Chan LC, Thompson A, Cleary ML, So CW. Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol 2007;9:1208-15. (Pubitemid 47500498)
25. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999;5:1369-79. (Pubitemid 29282941)
26. Kunsch C, Rubin SM, Rosen CA. Selection of optimal kappa B/Rel DNA-binding motifs: interaction of both subunits of NF-kappa B with DNA is required for transcriptional activation. Mol Cell Biol 1992;12: 4412-21.
27. Xu X, Gelinas CA. Mutant Rel-homology domain promotes transcription by p50/NFkappaB1. Oncogene 1997;14:1521-30. (Pubitemid 27182834)
28. Yang X, Lu H, Yan B, Romano RA, Bian Y, Friedman J, et al. DNp63 versatilely regulates a broad NF-kB gene program and promotes squamous epithelial proliferation, migration, and inflammation. Cancer Res 2011;71:3688-700.
29. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006;9:45-56. (Pubitemid 43069510)
30. Romano RA, Smalley K, Liu S, Sinha S. Abnormal hair follicle development and altered cell fate of follicular keratinocytes in transgenic mice expressing DeltaNp63alpha. Development 2010; 137:1431-9.
31. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NFkappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-3.
32. Ehsanian R, Brown M, Lu H, Yang XP, Pattatheyil A, Yan B, et al. YAP dysregulation by phosphorylation or DNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. Oncogene 2010;29:6160-71.
33. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/ p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007;117:1370-80. (Pubitemid 46718425)
34. Zangen R, Ratovitski E, Sidransky D. DeltaNp63alpha levels correlate with clinical tumor response to cisplatin. Cell Cycle 2005; 4:1313-5. (Pubitemid 41437109)
35. Gilmore TD, Kalaitzidis D, Liang MC, Starczynowski DT. The c-REL transcription factor and B-cell proliferation: a deal with the devil. Oncogene 2004;23:2275-86. (Pubitemid 38496782)
36. Gilmore TD, Garbati MR. Inhibition of NF-kB signaling as a strategy in disease therapy. In: Karin M, editor. NF-kB in health and disease. Berlin: Springer-Verlag; 2010. p. 245-63.
37. Chatterjee A, Chang X, Sen T, Ravi R, Bedi A, Sidransky D. Regulation of p53 family member isoform DeltaNp63 alpha by the nuclear factor kappaB targeting kinase IkappaB kinase beta. Cancer Res 2010; 70:1419-29.
38. Furuya K, Ozaki T, Hanamoto T, Hosoda M, Hayashi S, Barker PA, et al. Stabilization of p73 by nuclear IkappaB kinase-alpha mediates cisplatin- induced apoptosis. J Biol Chem 2007;282:18365-78. (Pubitemid 47100198)